Strides Pharma Science Ltd
Strides Pharma Science Ltd (STAR) last reported results for the quarter ended Jun 2026, with sales of ₹1,265 crore and net profit of ₹165 crore. The stock last traded at ₹1,083, a market capitalisation of ₹9,979 crore, on a P/E of 17.2. Over the past 52 weeks the stock has ranged between ₹769 and ₹1,261. Figures are as of 6 Oct 2026 and are not real time.
Strides Pharma Science Ltd share price and key metrics
- Current price
- ₹1,083
- Market cap
- ₹9,979 cr
- Stock P/E
- 17.2
- Book value
- ₹337
- ROE
- 20.0%
- ROCE
- 18.3%
- Dividend yield
- 0.46%
- 52w high / low
- 1261/769
Metrics as of 6 Oct 2026. Not real time.
Track Strides Pharma Science Ltd
Cruxal reads every Strides Pharma Science Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Strides Pharma Science Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 8%
- 3 Years
- 10%
- TTM
- 8%
- 10 Years
- 16%
- 5 Years
- 20%
- 3 Years
- 71%
- TTM
- 55%
- 10 Years
- 9%
- 5 Years
- 32%
- 3 Years
- 67%
- 1 Year
- 30%
- 10 Years
- 22%
- 5 Years
- 31%
- 3 Years
- 57%
- Last Year
- 20%
Strides Pharma Science Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,265 cr, up 12.9% from ₹1,120 cr a year earlier. Net profit was ₹165 cr, up 55.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Expenses | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 |
| Operating profit | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 |
| OPM % | 16% | 18% | 18% | 19% | 19% | 20% | 18% | 18% |
| Other income | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 |
| Interest | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| Profit before tax | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 |
| Tax % | 16% | 21% | 20% | 13% | 14% | 15% | 13% | 17% |
| Net profit | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS (₹) | 7.81 | 9.54 | 8.91 | 10.80 | 13.84 | 21.93 | 13.77 | 17.02 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Strides Pharma Science Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 | 5,004 |
| Operating profit | 527 | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 | 925 | 935 |
| OPM % | 19% | 14% | 9% | 15% | 16% | -4.3% | 3.9% | 14% | 18% | 19% | 19% |
| Net profit | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | 575 | 634 |
| EPS (₹) | 44.71 | 74.25 | 36.27 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 389.75 | 60.34 | 66.56 |
TTM is the trailing twelve months to the most recent quarter.
Strides Pharma Science Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 |
| Reserves | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,460 | 3,015 |
| Borrowings | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 1,880 | 1,758 |
| Other liabilities | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,498 | 1,941 |
| Total liabilities | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 |
| Fixed assets | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 | 2,101 |
| CWIP | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 | 447 |
| Investments | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 |
| Other assets | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,414 | 3,967 |
| Total assets | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 |
As reported by the company. Total assets equal total liabilities by construction.
Strides Pharma Science Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Cash from investing | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 | -173 |
| Cash from financing | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | -453 |
| Net cash flow | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 | 76 |
| Free cash flow | -386 | -212 | -256 | 58 | 188 | -326 | -43 | 672 | 505 | 291 |
| CFO / operating profit | 66% | 61% | 59% | 60% | 60% | 199% | -30% | 128% | 77% | 84% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Strides Pharma Science Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 11% | 16% | 2% | 5% | 8% | -5% | -0% | 7% | 15% | 18% |
| Debtor days | 132 | 113 | 165 | 124 | 122 | 144 | 129 | 107 | 96 | 97 |
| Inventory days | 209 | 146 | 294 | 254 | 329 | 285 | 257 | 235 | 236 | 305 |
| Days payable | 221 | 188 | 299 | 259 | 323 | 260 | 220 | 178 | 190 | 244 |
| Cash conversion cycle | 120 | 71 | 160 | 119 | 128 | 168 | 165 | 164 | 141 | 157 |
| Working capital days | -122 | -4 | -70 | -70 | -22 | -28 | -11 | -19 | 24 | 38 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Strides Pharma Science Ltd shareholding pattern
Promoters held 27.91% at Jun 2026, broadly unchanged since Jun 2025. FIIs 28.40% and DIIs 15.42%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 25.84% | 26.82% | 28.30% | 28.30% | 27.86% | 27.86% | 27.91% | 27.91% |
| FIIs | 30.08% | 28.48% | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.40% |
| DIIs | 18.24% | 16.92% | 13.72% | 13.30% | 12.98% | 13.02% | 14.44% | 15.42% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 25.83% | 27.78% | 29.65% | 30.38% | 30.62% | 29.59% | 28.96% | 28.28% |
| No. of shareholders | 96,009 | 1,14,236 | 95,125 | 92,889 | 91,206 | 85,589 | 86,616 | 94,850 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Strides Pharma Science Ltd
Strides Pharma Science Ltd corporate filings
- Certificate in terms of regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026Company Updatelow impact
- Closure of Trading Window for the quarter ended September 30, 2026Insider Trading / SASTlow impact
- Strides Pharma Science Ltd releases Sustainability Report for FY26Company Updatelow impact
Cruxal's analysis: Strides Pharma Science Ltd has filed its Sustainability Report for the fiscal year 2026…
Read the full analysis - Strides Pharma Science completes USFDA inspection at Alathur formulation facilityCompany Updatemedium impact
Cruxal's analysis: Strides Pharma Science has announced the successful completion of a USFDA inspection at…
Read the full analysis - Strides Pharma Science receives USFDA Establishment Inspection Report (EIR) for Bengaluru facilityCompany Updatemedium impact
Cruxal's analysis: Strides Pharma Science has received the Establishment Inspection Report (EIR) from the…
Read the full analysis - Strides Pharma Science Limited concludes 35th AGM; all resolutions passed including final dividend declarationAGM/EGMlow impact
Cruxal's analysis: Strides Pharma Science Limited has successfully concluded its 35th Annual General Meeting…
Read the full analysis - Strides Pharma Science Limited concludes 35th Annual General Meeting; confirms clean audit reportsAGM/EGMlow impact
Cruxal's analysis: Strides Pharma Science Limited successfully conducted its 35th Annual General Meeting on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.